UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

Peterson, RL; Vock, DM; Powers, JH; Emery, S; Cruz, EF; Hunsberger, S; Jain, MK; ... Neaton, JD; + view all (2017) Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clinical Trials , 14 (3) pp. 264-276. 10.1177/1740774517697919. Green open access

[thumbnail of Pett_Prop_Odds_Paper_Revised_Clean.pdf]
Preview
Text
Pett_Prop_Odds_Paper_Revised_Clean.pdf - Accepted Version

Download (482kB) | Preview

Abstract

BACKGROUND/AIMS: A single best endpoint for evaluating treatments of severe influenza requiring hospitalization has not been identified. A novel six-category ordinal endpoint of patient status is being used in a randomized controlled trial (FLU-Intravenous Immunoglobulin - FLU-IVIG) of intravenous immunoglobulin. We systematically examine four factors regarding the use of this ordinal endpoint that may affect power from fitting a proportional odds model: (1) deviations from the proportional odds assumption which result in the same overall treatment effect as specified in the FLU-IVIG protocol and which result in a diminished overall treatment effect, (2) deviations from the distribution of the placebo group assumed in the FLU-IVIG design, (3) the effect of patient misclassification among the six categories, and (4) the number of categories of the ordinal endpoint. We also consider interactions between the treatment effect (i.e. factor 1) and each other factor. METHODS: We conducted a Monte Carlo simulation study to assess the effect of each factor. To study factor 1, we developed an algorithm for deriving distributions of the ordinal endpoint in the two treatment groups that deviated from proportional odds while maintaining the same overall treatment effect. For factor 2, we considered placebo group distributions which were more or less skewed than the one specified in the FLU-IVIG protocol by adding or subtracting a constant from the cumulative log odds. To assess factor 3, we added misclassification between adjacent pairs of categories that depend on subjective patient/clinician assessments. For factor 4, we collapsed some categories into single categories. RESULTS: Deviations from proportional odds reduced power at most from 80% to 77% given the same overall treatment effect as specified in the FLU-IVIG protocol. Misclassification and collapsing categories can reduce power by over 40 and 10 percentage points, respectively, when they affect categories with many patients and a discernible treatment effect. But collapsing categories that contain no treatment effect can raise power by over 20 percentage points. Differences in the distribution of the placebo group can raise power by over 20 percentage points or reduce power by over 40 percentage points depending on how patients are shifted to portions of the ordinal endpoint with a large treatment effect. CONCLUSION: Provided that the overall treatment effect is maintained, deviations from proportional odds marginally reduce power. However, deviations from proportional odds can modify the effect of misclassification, the number of categories, and the distribution of the placebo group on power. In general, adjacent pairs of categories with many patients should be kept separate to help ensure that power is maintained at the pre-specified level.

Type: Article
Title: Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/1740774517697919
Publisher version: http://dx.doi.org/10.1177/1740774517697919
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Clinical trials, endpoints, proportional odds model, misspecified model, statistical power, TRAUMATIC BRAIN-INJURY, INTRAVENOUS PERAMIVIR, CLINICAL-TRIALS
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/1552929
Downloads since deposit
80Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item